Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...

BioWorld’s three-part analysis of M&As sought to discover successful transactions and to understand the trend of multibillion-dollar deals that have become commonplace in the last decade. Instead, ...

The U.K. is continuing to shape up regulation, adding reform of its accelerated drug approval process and its draft guidance on personalized mRNA cancer vaccines to new clinical trial regulations that ...

Arbor Biotechnologies Inc.’s ABO-101 has been awarded orphan drug and rare pediatric disease designations by the FDA for the treatment of primary hyperoxaluria type 1 (PH1).

Redx Pharma plc has divulged Rho kinase 1 (ROCK1) and 2 (ROCK2) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, fibrosis, inflammatory and neurological disorders.

Curently the only available blood test to tell which women are at risk of postpartum depression (PPD) is the one that ...

Merck Sharp & Dohme LLC has identified targeted activator of cell kill (TACK) compounds acting as Gag polyprotein (HIV-1)/protein Pol dimerization inducers reported to be useful for the treatment of ...

Shanghai Yidi Biotechnology Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to an androgen receptor targeting moiety via a linker reported ...

Oncolytic viruses are therapeutic agents used for in situ immunization in cancer immunotherapy. Unfortunately, its efficacy is particularly limited in solid tumors expressing stimulator of interferon ...

Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of neurodegeneration.